Big Rise Is Predicted In Biotech Job Market

The results of the employment survey come from Mark Dibner, director of the North Carolina Bio- technology Center in Research Triangle Park. Dibner’s study confirmed that most of the companies surveyed had started small— averaging only 13 employees by the end of their first year. Most, however, showed significant growth, with one firm mushrooming to 160 employees by the end of its first year. On average, the companies surveyed had 86 employees after six years. The center’s

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The results of the employment survey come from Mark Dibner, director of the North Carolina Bio- technology Center in Research Triangle Park. Dibner’s study confirmed that most of the companies surveyed had started small— averaging only 13 employees by the end of their first year. Most, however, showed significant growth, with one firm mushrooming to 160 employees by the end of its first year. On average, the companies surveyed had 86 employees after six years.

The center’s questionnaire then asked the biotech company managers to project what their staff levels would be five years from now. According to the responses, the firms’ staffs are expected to grow by 27% annually, with the average soaring from the 86-employee average now to well over 200 five years from now.

Dibner says that as this growth progresses, the kind of jobs available in the biotech industry will change. He found that production and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies